



Applicant : Toufic RENNO and Jean-Yves BONNEFOY

Serial No. : 09/913,772

Filed : September 24, 2001

Title : USE OF AN ENTERBACTERIUM OmpA PROTEIN COMBINED WITH AN ANTIGEN, FOR GENERATING AN ANTIVIRAL, ANTIPARASITIC OR ANTITUMOR CYTOTOXIC RESPONSE

Art Unit : 1645

Examiner : Robert A. ZEMAN, Esq.

* * * * *

Honorable Commissioner of Patents and Trademarks

Alexandria, VA 22313

STATEMENT UNDER 37 CFR § 1.821(f)

Sir:

The undersigned attorney does hereby state that, to the best of his knowledge and understanding, the accompanying substitute Sequence Listing in computer readable form is the same as the accompanying substitute Sequence Listing in paper copy form.

Respectfully submitted,

THE FIRM OF HUESCHEN AND SAGE


G. PATRICK SAGE, Attorney #37,710

Dated: February 24, 2005
Customer No. 25,666
500 Columbia Plaza
350 East Michigan Avenue
Kalamazoo, MI 49007
(269) 382-0030

Enclosure: Sequence Listing in diskette form and paper form.

FEB. 28 2005 - BPC

Application No.: 09/913,772

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- 7. Other: the specification contains sequences without the requisite sequence identifiers (see page 22, line 19 and page 23 lines 6 and 36 for example.

Applicant Must Provide:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY